Plasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial progenitor cells in patients with newly diagnosed hypertension

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 6, 2012, Pages 1107-1113

  Bogdanski, Pawel ^a   Miller Kasprzak, Ewa ^a   Pupek Musialik, Danuta ^a   Jablecka, Anna ^a   Lacinski, Mariusz ^a   Jagodzinski, Piotr P ^a   Jakubowski, Hieronim ^b,c,d  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^c INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Endothelial progenitor cells; Homocysteine; Hypertension; Intima media thickness; Total antioxidant status

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; LIPID; ANTIOXIDANT;

ADULT; AMINO ACID BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; BIOCHEMISTRY; BLOOD; CAROTID ARTERY; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM INJURY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; LIPID BLOOD LEVEL; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; ULTRASOUND TRANSDUCER; ENDOTHELIUM; HYPERTENSION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; STEM CELL;

ADULT; ANTIOXIDANTS; CAROTID INTIMA-MEDIA THICKNESS; ENDOTHELIUM; HOMOCYSTEINE; HUMANS; HYPERTENSION; OXIDATIVE STRESS; STEM CELLS;

EID: 84867412559     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0856     Document Type: Article

References (51)

1. McCully K. Vascular pathology of homocysteine: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
2. Wald D, Law M, Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202.
3. Khandanpour N, Loke Y, Meyer F, Jennings B, Armon M. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2009;38:316-22.
4. Kalita J, Kumar G, Bansal V, Misra U. Relationship of homocysteine with other risk factors and outcome of ischemic stroke. Clin Neurol Neurosurg 2009;111:364-7.
5. Park C, Ihm S, Yoo K, Kim D, Lee J, Kim H, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010;105:1284-8.
6. Welch G, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
7. Lentz S. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005;3:1646-54.
8. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 2004;61:470-87.
9. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001;55:443-7.
10. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006;26:1397-404.
11. Jakubowski H, Boers G, Strauss K. Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J 2008;22:4071-6.
12. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin Chem Lab Med 2005;43:1011-4.
13. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H. Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients. Biomed Pharmacother 2008;62:360-5.
14. Hill J, Zalos G, Halcox J, Schenke W, Waclawiw M, Quyyumi A, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
15. Miller-Kasprzak E, Jagodziński P. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp (Warsz) 2007;55:247-59.
16. Hristov M, Fach C, Becker C, Heussen N, Liehn E, Blindt R, et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 2007;192:413-20.
17. Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
18. Capobianco S, Chennamaneni V, Mittal M, Zhang N, Zhang C. Endothelial progenitor cells as factors in neovascularization and endothelial repair. World J Cardiol 2010;2:411-20.
19. Sen S, McDonald S, Coates P, Bonder C. Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond) 2011;120:263-83.
20. Yang Z, Chen L, Su C, Xia W, Wang Y, Wang J, et al. Impaired endothelial progenitor cell activity is associated with reduced arterial elasticity in patients with essential hypertension. Clin Exp Hypertens 2010;32:444-52.
21. MacEneaney O, Kushner E, Van Guilder G, Greiner J, Stauffer B, De Souza C. Endothelial progenitor cell number and colonyforming capacity in overweight and obese adults. Int J Obes (Lond) 2009;33:219-25.
22. Miller-Kasprzak E, Bogdański P, Pupek-Musialik D, Jagodziński P. Insulin resistance and oxidative stress influence colony-forming unit-endothelial cells capacity in obese patients. Obesity (Silver Spring) 2011;19:736-42.
23. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
24. Wong W, Wong S, Tian X, Huang Y. Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 2010;55:300-7.
25. De La Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010;24:373-9.
26. Touboul P, Labreuche J, Vicaut E, Amarenco P, GENIC Investigators. Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk. Stroke 2005;36:1741-5.
27. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007;25:2463-70.
28. Di Bello V, Carerj S, Perticone F, Benedetto F, Palombo C, Talini E, et al. Research Group of the Italian Society of Cardio Vascular Echocardiography (SIEC). Carotid intima-media thickness in asymptomatic patients with arterial hypertension without clinical cardiovascular disease: relation with left ventricular geometry and mass and coexisting risk factors. Angiology 2009;60:705-13.
29. Napoli C, Bruzzese G, Ignarro L, Crimi E, De Nigris F, Williams-Ignarro S, et al. Long-term treatment with sulfhydryl angiotensinconverting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008;156:1-8.
30. Kleber M, Wolfert R, De Moissl G, Grammer T, Dietz S, Winkelmann B, et al. Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Lab 2011;57:659-67.
31. Pasceri V, Willerson J, Yeh E. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
32. Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
33. Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski J. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009;204:239-43.
34. Schillaci G, Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006;16:500-8.
35. D'Odorico A, Martines D, Kiechl S, Egger G, Oberhollenzer F, Bonvicini P, et al. High plasma levels of alpha-and beta-carotene are associated with a lower risk of atherosclerosis: results from the Bruneck study. Atherosclerosis 2000;153:231-9.
36. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9.
37. Kaul S, Zadeh A, Shah P. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006;48:914-23.
38. Antoniades C, Antonopoulos A, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009;30:6-15.
39. Bowman T, Gaziano J, Stampfer M, Sesso H. Homocysteine and risk of developing hypertension in men. J Hum Hypertens 2006;20:631-4.
40. Ruan L, Chen W, Srinivasan S, Xu J, Toprak A, Berenson G. Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). Am J Cardiol 2010;106:793-7.
41. Zhu J, Wang X, Chen J, Sun J, Zhang F. Reduced number and activity of circulating endothelial progenitor cells from patients with hyperhomocysteinemia. Arch Med Res 2006;37:484-9.
42. Chen J, Zhu J, Wang X. Effects of hypercholesterolemia on the number and activity of endothelial progenitor cells in peripheral blood. Zhonghua Nei Ke Za Zhi 2004;43:261-4.
43. Alvarez-Maqueda M, El Bekay R, Monteseirin J, Alba G, Chacón P, Vega A, et al. Homocysteine enhances superoxide anion release and NADPH oxidase assembly by human neutrophils. Effects on MAPK activation and neutrophil migration. Atherosclerosis 2004;172:229-38.
44. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 2005;6:27-36.
45. Glowacki R, Jakubowski H. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 2004;279:10864-71.
46. Ventura E, Durant R, Jaussent A, Picot M, Morena M, Badiou S, et al. Homocysteine and inflammation as main determinants of oxidative stress in the elderly. Free Radic Biol Med 2009;46:737-44.
47. Siow Y, Au-Yeung K, Woo C. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J 2006;398:73-82.
48. Becker J, Adler A, Schneeberger A, Huang H, Wang Z, Walsh E, et al. Hyperhomocysteinemia, a cardiac metabolic disease: role of nitric oxide and the p22phox subunit of NADPH oxidase. Circulation 2005;111:2112-8.
49. Bao X, Wu C, Lu G. Atorvastatin inhibits homocysteineinduced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis 2010;210:114-21.
50. Friso S, Jacques P, Wilson P, Rosenberg I, Selhub J. Low circulating vitamin B (6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103:2788-91.
51. Rohde L, Hennekens C, Ridker P. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:1018-22.